| 1 |
Alayo QA, Loftus EV Jr, Yarur A, Alvarado D, Ciorba MA, de Las Fuentes L, Deepak P. Inflammatory Bowel Disease Is Associated With an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank. Clin Gastroenterol Hepatol 2023;21:761-770.e13. [PMID: 36075499 DOI: 10.1016/j.cgh.2022.08.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 2 |
Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 2023;43:421-35. [PMID: 36635577 DOI: 10.1007/s00296-022-05270-6] [Reference Citation Analysis]
|
| 3 |
Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, Serrero M, Leclerc E, Caillo L, Pereira B, Amiot A, Bouguen G. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther 2023;57:676-88. [PMID: 36401585 DOI: 10.1111/apt.17305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, Narula N, Tsai C, Peerani F, Reise-Filteau M, Bressler B, Starkey SY, Loomes D, Sedano R, Jairath V, Bessissow T; Canadian IBD Research Consortium. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study. Am J Gastroenterol 2023. [PMID: 36580497 DOI: 10.14309/ajg.0000000000002129] [Reference Citation Analysis]
|
| 5 |
Laredo V, García-Mateo S, Martínez-Domínguez SJ, López de la Cruz J, Gargallo-Puyuelo CJ, Gomollón F. Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. Cancers (Basel) 2023;15. [PMID: 36765829 DOI: 10.3390/cancers15030871] [Reference Citation Analysis]
|
| 6 |
Sousa P, Bertani L, Rodrigues C. Management of inflammatory bowel disease in the elderly: A review. Dig Liver Dis 2023:S1590-8658(22)00873-8. [PMID: 36681569 DOI: 10.1016/j.dld.2022.12.024] [Reference Citation Analysis]
|
| 7 |
Shin SH, Oh K, Hong SN, Lee J, Oh SJ, Kim ES, Na SY, Kang SB, Koh SJ, Bang KB, Jung SA, Jung SH, Kim KO, Park SH, Yang SK, Choi CH, Ye BD. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. Therap Adv Gastroenterol 2023;16:17562848231154103. [PMID: 36950251 DOI: 10.1177/17562848231154103] [Reference Citation Analysis]
|
| 8 |
Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen-de Jong AE, Duijvestein M. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry. Aliment Pharmacol Ther 2023;57:117-26. [PMID: 36282200 DOI: 10.1111/apt.17248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Kutschera M, Novacek G, Reinisch W, Högenauer C, Petritsch W, Haas T, Moschen A, Dejaco C. Tofacitinib in the treatment of ulcerative colitis : A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH). Wien Klin Wochenschr 2023;135:1-13. [PMID: 36454302 DOI: 10.1007/s00508-022-02110-2] [Reference Citation Analysis]
|
| 10 |
Chaparro M, Acosta D, Rodríguez C, Mesonero F, Vicuña M, Acosta MB, Fernández-Clotet A, Martínez ÁH, Arroyo M, Vera I, Ruiz-Cerulla A, Sicilia B, Cabello Tapia MJ, Villafranca CM, Castro-Poceiro J, Cadilla JM, Sierra-Ausín M, Vázquez Morón JM, Lidón RV, Bermejo F, Royo V, Calafat M, González-Muñoza C, Carnerero EL, Marcos NM, Torrealba L, Alonso-Galán H, Benítez JM, Nieto YB, Diz-Lois Palomares MT, García MJ, Muñoz JF, Armesto González EM, Calvet X, Hernández-Camba A, Madrigal Domínguez RE, Menchén L, Pérez Calle JL, Piqueras M, Sadornil CD, Botella B, de Jesús Martínez-Pérez T, Ramos L, Rodríguez-Grau MC, San Miguel E, Fernández Forcelledo JL, Fradejas Salazar PM, García-Sepulcre M, Gutiérrez A, Llaó J, Abizanda ES, Boscá-Watts M, Iyo E, Keco-Huerga A, Bonil CM, González EP, Pérez-Galindo P, Varela P, Gisbert JP. Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety. Am J Gastroenterol 2022. [PMID: 36716287 DOI: 10.14309/ajg.0000000000002145] [Reference Citation Analysis]
|
| 11 |
Boccatonda A, Balletta M, Vicari S, Hoxha A, Simioni P, Campello E. The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review. Semin Thromb Hemost 2022. [DOI: 10.1055/s-0042-1758869] [Reference Citation Analysis]
|
| 12 |
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2022;75:724-30. [PMID: 36122389 DOI: 10.1097/MPG.0000000000003616] [Reference Citation Analysis]
|
| 13 |
Kakiuchi T, Yoshiura M. Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report. Medicine (Baltimore) 2022;101:e31757. [PMID: 36397383 DOI: 10.1097/MD.0000000000031757] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Taneja V, El-Dallal M, Haq Z, Tripathi K, Systrom HK, Wang LF, Said H, Bain PA, Zhou Y, Feuerstein JD. Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Systematic Review and Meta-analysis. J Clin Gastroenterol 2022;56:e323-33. [PMID: 34516458 DOI: 10.1097/MCG.0000000000001608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 15 |
Pan X, Zhu Q, Pan L, Sun J. Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy. Pharmacology & Therapeutics 2022;238:108176. [DOI: 10.1016/j.pharmthera.2022.108176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Matsuoka K, Hisamatsu T, Kim HJ, Ye BD, Arai S, Hoshi M, Yuasa H, Tabira J, Toyoizumi S, Shi N, Woo JS, Hibi T. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. J Gastroenterol Hepatol 2022;37:1884-92. [PMID: 35734858 DOI: 10.1111/jgh.15923] [Reference Citation Analysis]
|
| 17 |
Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Busnadiego I, Abela IA, Frey PM, Hofmaenner DA, Scheier TC, Schuepbach RA, Buehler PK, Brugger SD, Hale BG. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol 2022;20:e3001709. [PMID: 35788562 DOI: 10.1371/journal.pbio.3001709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Sekhri S, Yarur AJ. Integrating new and emerging therapies into inflammatory bowel disease clinical practice. Curr Opin Gastroenterol 2022;38:328-36. [PMID: 35762692 DOI: 10.1097/MOG.0000000000000851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Gergely M, Prado E, Deepak P. Management of refractory inflammatory bowel disease. Curr Opin Gastroenterol 2022;38:347-57. [PMID: 35762694 DOI: 10.1097/MOG.0000000000000849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
|
| 22 |
Elmariah SB, Smith JS, Merola JF. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. Am J Clin Dermatol 2022. [PMID: 35679017 DOI: 10.1007/s40257-022-00701-3] [Reference Citation Analysis]
|
| 23 |
Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02215-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Busnadiego I, Abela IA, Frey PM, Hofmaenner DA, Scheier TC, Schuepbach RA, Buehler PK, Brugger SD, Hale BG. Herpesvirus Reactivations in Critically-Ill COVID-19 Patients with Autoantibodies Neutralizing Type I Interferons.. [DOI: 10.1101/2022.03.19.22272532] [Reference Citation Analysis]
|
| 25 |
Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Spiewak TA, Patel A. User's Guide to JAK Inhibitors in Inflammatory Bowel Disease. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Taxonera C. Editorial: real-world safety of tofacitinib in ulcerative colitis. Aliment Pharmacol Ther 2022;55:368-9. [PMID: 35040163 DOI: 10.1111/apt.16740] [Reference Citation Analysis]
|
| 28 |
Mishra S, Kumar Singh A, Kopp C, Jena A, Sharma V. Tubercular Pleural Effusion in a Patient of Ulcerative Colitis Treated With Tofacitinib. Inflamm Bowel Dis 2022;28:e24. [PMID: 34525193 DOI: 10.1093/ibd/izab234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Katsanos KH, Armuzzi A. Effectiveness and safety of tofacitinib in ulcerative colitis: Done is better than perfect. Dig Liver Dis 2022;54:151-3. [PMID: 34953762 DOI: 10.1016/j.dld.2021.11.017] [Reference Citation Analysis]
|
| 30 |
Alayo QA, Fenster M, Altayar O, Glassner KL, Llano E, Clark-Snustad K, Patel A, Kwapisz L, Yarur AJ, Cohen BL, Ciorba MA, Thomas D, Lee SD, Loftus EV Jr, Fudman DI, Abraham BP, Colombel JF, Deepak P. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohns Colitis 360 2022;4:otac002. [PMID: 35310082 DOI: 10.1093/crocol/otac002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 31 |
Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021;13:1828-49. [PMID: 35069993 DOI: 10.4254/wjh.v13.i12.1828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 32 |
Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx LAAP, Jones GR, Lees CW. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211064004. [PMID: 34987608 DOI: 10.1177/17562848211064004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 33 |
Colitis ulcerosa: Studie untersucht Nebenwirkungen der Tofacitinib-Behandlung. Z Gastroenterol 2021;59:1140-1140. [DOI: 10.1055/a-1609-1351] [Reference Citation Analysis]
|
| 34 |
Fenster M, Alayo QA, Khatiwada A, Wang W, Dimopoulos C, Gutierrez A, Ciorba MA, Christophi GP, Hirten RP, Ha C, Beniwal-Patel P, Cohen BL, Syal G, Yarur A, Patel A, Colombel JF, Pekow J, Ungaro RC, Rubin DT, Deepak P. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol 2021;19:2207-2209.e3. [PMID: 33068786 DOI: 10.1016/j.cgh.2020.10.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 35 |
Song HY, Seo GS. Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies. J Korean Med Assoc 2021;64:605-13. [DOI: 10.5124/jkma.2021.64.9.605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 36 |
Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol 2021;37:344-50. [PMID: 33731642 DOI: 10.1097/MOG.0000000000000738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Alayo QA, Khatiwada A, Patel A, Zulfiqar M, Gremida A, Gutierrez A, Rood RP, Ciorba MA, Christophi G, Deepak P. Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:1698-702. [PMID: 34037225 DOI: 10.1093/ibd/izab112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 38 |
Lucaciu L, Constantine-cooke N, Plevris N, Siakavellas S, Derikx L, Jones G, Lees C. Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis.. [DOI: 10.1101/2021.04.27.21256170] [Reference Citation Analysis]
|
| 39 |
Coremans L, Strubbe B, Peeters H. Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms. Acta Gastroenterol Belg 2021;84:79-85. [PMID: 33639697 DOI: 10.51821/84.1.910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 40 |
Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:857-73. [PMID: 34453143 DOI: 10.1038/s41575-021-00492-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 41 |
Alayo QA, Khatiwada A, Patel A, Zulfiqar M, Gremida A, Gutierrez A, Rood RP, Ciorba MA, Christophi G, Deepak P. Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases.. [DOI: 10.1101/2020.10.18.20214841] [Reference Citation Analysis]
|
